RT Book, Section
A1 Shinkai, Kanade
A1 Fox, Lindy P.
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184190254
T1 Bullous Pemphigoid
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184190254
RD 2024/04/19
AB Bullous  pemphigoid  is  a  relatively  benign  pruritic  disease  characterized  by  tense  blisters  in  flexural  areas,  usually  remitting  in  5  or  6  years,  with  a  course  characterized  by  exacerbations  and  remissions  (eFigure  6–77)  (eFigure  6–78).  Most  affected  persons  are  over  the  age  of  60  and  men  are  affected  twice  as  frequently  as  women.  The  appearance  of  blisters  may  be  preceded  by  pruritic  urticarial  or  edematous  lesions  for  months.  Oral  lesions  are  present  in  one-third.  The  disease  may  occur  in  various  forms,  including  localized,  vesicular,  vegetating,  erythematous,  erythrodermic,  and  nodular.  Drugs  may  induce  bullous  pemphigoid.  The  most  common  offender  is  furosemide.  Immunotherapy  for  malignancies  with  PD-1  inhibitors  can  cause  drug-induced  bullous  pemphigoid.